{"status": "OK", "response": {"docs": [{"type_of_material": "Blog", "blog": [], "news_desk": null, "lead_paragraph": "Novartis has agreed to buy Nestle's majority stake in Alcon, the United States-based eye care business, in a deal worth up to $39 billion.", "headline": {"main": "Nestle in $39 Billion Deal to Sell Alcon", "kicker": "DealBook"}, "abstract": "Novartis has agreed to buy Nestle's majority stake in Alcon, the United States-based eye care business, in a deal worth up to $39 billion. Novartis, the Swiss drugmaker, will acquire a first, 25 percent stake in Alcon for $11 billion and is set to buy Nestle's remaining 52 percent for a fixed price of $28 [...]", "print_page": null, "word_count": 586, "_id": "4fd36b7f8eb7c8105d8c05d1", "snippet": "Novartis has agreed to buy Nestle's majority stake in Alcon, the United States-based eye care business, in a deal worth up to $39 billion. Novartis, the Swiss drugmaker, will acquire a first, 25 percent stake in Alcon for $11 billion and is set to...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://dealbook.nytimes.com/2008/04/07/novartis-signs-39-billion-deal-for-nestles-alcon-stake/", "multimedia": [], "subsection_name": null, "keywords": [{"value": "News", "name": "type_of_material", "rank": "1"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1}], "original": "By DEALBOOK"}, "document_type": "blogpost", "pub_date": "2008-04-07T07:02:50Z", "section_name": "Business Day"}, {"type_of_material": "News", "blog": [], "news_desk": "Magazine", "lead_paragraph": "Can Barack Obama capture the lunch-pail Democrats of Pennsylvania? The author returns to his hometown to see.", "headline": {"seo": "Barack Obama - Hillary Clinton - Levittown - Pennsylvania. - Presidential Election of 2008 - Democrats - Elections - Race", "main": "Change Makes a Call on Levittown", "print_headline": "Change Makes A Call on Levittown"}, "abstract": null, "print_page": "46", "word_count": "5084", "_id": "5479e9f7798810519966975a", "snippet": "Can Barack Obama capture the lunch-pail Democrats of Pennsylvania? The author returns to his hometown to see.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2008/04/06/magazine/06race-t.html", "multimedia": [{"width": 600, "url": "images/2008/04/06/magazine/06race-600.jpg", "height": 330, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlarge": "images/2008/04/06/magazine/06race-600.jpg", "xlargeheight": "330"}, "type": "image"}, {"width": 75, "url": "images/2008/04/06/magazine/06race-75.jpg", "height": 75, "subtype": "thumbnail", "legacy": {"thumbnailheight": "75", "thumbnail": "images/2008/04/06/magazine/06race-75.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"rank": "1", "is_major": "N", "value": "Obama, Barack", "name": "persons"}, {"rank": "2", "is_major": "N", "value": "Pennsylvania", "name": "glocations"}, {"rank": "3", "is_major": "N", "value": "Clinton, Hillary Rodham", "name": "persons"}, {"rank": "4", "is_major": "N", "value": "Race", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Blacks", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Elections", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Presidential Election of 2008", "name": "subject"}, {"rank": "8", "is_major": "N", "value": "Primaries", "name": "subject"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Michael", "rank": 1, "lastname": "SOKOLOVE"}], "original": "By MICHAEL SOKOLOVE"}, "document_type": "article", "pub_date": "2008-04-06T00:00:00Z", "section_name": "Magazine"}, {"type_of_material": "Question", "blog": [], "news_desk": "Science", "lead_paragraph": "Dr. Kevin T. McVary on erectile dysfunction, Botox and enlarged prostates", "headline": {"main": "New Therapies in the B.P.H. Pipeline", "kicker": "Expert Q & A", "print_headline": "New Therapies in the B.P.H. Pipeline", "content_kicker": "Expert Q & A"}, "abstract": null, "print_page": null, "word_count": "1233", "_id": "5342c3817988107fc3649fb8", "snippet": "Dr. Kevin T. McVary on erectile dysfunction, Botox and enlarged prostates", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/ref/health/healthguide/esn-bph-expert.html", "multimedia": [], "subsection_name": "Health Guide", "keywords": [{"value": "Bladder", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Prostate Gland", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Viagra (Drug)", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Medicine and Health", "is_major": "N", "rank": "4", "name": "subject"}], "byline": {"person": [{"firstname": "Gerald", "middlename": "Secor", "lastname": "COUZENS", "rank": 1, "role": "reported", "organization": ""}], "original": "By GERALD SECOR COUZENS"}, "document_type": "article", "pub_date": "2008-04-04T00:00:00Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Science", "lead_paragraph": "Clinical trials now accepting participants.", "headline": {"main": "Selected Studies: B.P.H.", "kicker": "Clinical Trials", "print_headline": "Selected Studies: B.P.H.", "content_kicker": "Clinical Trials"}, "abstract": null, "print_page": null, "word_count": "247", "_id": "5342c37d7988107fc3649fb5", "snippet": "Clinical trials now accepting participants.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/ref/health/healthguide/esn-bph-trials.html", "multimedia": [], "subsection_name": "Health Guide", "keywords": [{"value": "Medicine and Health", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Prostate Gland", "is_major": "N", "rank": "1", "name": "subject"}], "byline": null, "document_type": "article", "pub_date": "2008-04-04T00:00:00Z", "section_name": "Health"}, {"type_of_material": "Editorial", "blog": [], "news_desk": "Editorial", "lead_paragraph": "Heart experts are surely right that Vytorin and Zetia should be a last resort for patients who can\u2019t get their cholesterol down any other way.", "headline": {"main": "Overpromoted Cholesterol Drugs", "print_headline": "Overpromoted Cholesterol Drugs", "content_kicker": "Editorial"}, "abstract": null, "print_page": "26", "word_count": "491", "_id": "547fcc5b7988105a33db5e16", "snippet": "Heart experts are surely right that Vytorin and Zetia should be a last resort for patients who can\u2019t get their cholesterol down any other way.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2008/04/02/opinion/02wed2.html", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Zetia (Drug)", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Editorials", "is_major": "N", "rank": "11", "name": "subject"}, {"value": "Vytorin (Drug)", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Cholesterol", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Medicine and Health", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Statins (Cholesterol-Lowering Drugs)", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Advertising and Marketing", "is_major": "N", "rank": "6", "name": "subject"}, {"value": "Heart", "is_major": "N", "rank": "7", "name": "subject"}, {"value": "New England Journal of Medicine", "is_major": "N", "rank": "8", "name": "organizations"}, {"value": "Merck & Company Inc", "is_major": "N", "rank": "9", "name": "organizations"}, {"value": "Schering Plough Corp", "is_major": "N", "rank": "10", "name": "organizations"}], "byline": null, "document_type": "article", "pub_date": "2008-04-02T00:00:00Z", "section_name": "Opinion"}, {"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "A study published by the journal Nature is raising doubts about one of the hottest fields in biotechnology, RNA interference.", "headline": {"main": "Study Is Setback for Some RNA-Based Drugs", "kicker": "Market Place", "print_headline": "Study Raises Doubts on a Gene-Based Therapy", "content_kicker": "Market Place"}, "abstract": null, "print_page": "2", "word_count": "943", "_id": "547fc8167988105a33db5dba", "snippet": "A study published by the journal Nature is raising doubts about one of the hottest fields in biotechnology, RNA interference.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2008/04/02/business/02place.html", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Biotechnology", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Opko Health Incorporated", "is_major": "N", "rank": "2", "name": "organizations"}, {"value": "Allergan Incorporated", "is_major": "N", "rank": "3", "name": "organizations"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2008-04-02T00:00:00Z", "section_name": "Business Day"}], "meta": {"hits": 6, "offset": 0, "time": 30}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}